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Evaluating strategies to manage 
and endure challenging behaviors 
in mucopolysaccharidoses
Nathan Grant1*  
Abstract 
The mucopolysaccharidoses (MPS) are a group of rare, genetic, lysosomal storage disorders characterized by progres-
sive, multisystemic accumulation of glycosaminoglycans. Individuals with severe MPS often present with significant 
neurological involvement and may exhibit challenging behaviors, including hyperactivity, aggression, and sleep 
disturbance. These behaviors can cause adverse outcomes and necessitate the development of specific measures to 
support affected families. Through an analysis of the results reported by Hoffmann et al. in their recent study, this let-
ter outlines important factors that must be considered when evaluating the impact of challenging behaviors associ-
ated with MPS, including treatment history, age, sibling and family relationships, the feasibility of daily caregiving, 
and caregiver burden. These recommendations can help guide future studies to identify the most effective coping 
strategies to support families of people with MPS who have challenging behaviors.
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For many years, my family has struggled to provide care 
for my twin brother because of his challenging behaviors. 
My brother has the neuronopathic form of mucopolysac-
charidosis (MPS) type II, also known as severe Hunter 
syndrome. Like many people with this condition, my 
brother is nonverbal, has a significant intellectual disabil-
ity, and requires continual care and assistance from mul-
tiple caregivers [1, 2]. Although my parents and I assist 
my brother with daily living activities, including dress-
ing, feeding, bathing, and toileting, it can be extremely 
difficult to provide care when my brother is agitated and 
aggressive. In the midst of changing my brother’s diaper 
or dressing him, we have to carefully watch my brother’s 
hands to ensure he does not punch us or pull our hair. 
Our attempts at self-defense are usually futile, however, 
leaving us with bruises running up our arms, scratches 
around our necks, torn clothes, and hair left scattered on 
the ground. Since my brother is nonverbal, it is difficult 
to ascertain the specific causes of his aggression and we 
have not found any strategies to effectively manage his 
challenging behaviors. My family lives in constant fear of 
my brother’s next aggressive outburst, uncertain whether 
he approaches us to hug us or to harm us. The recent 
study by Hoffmann et  al. [3] provides important and 
timely insights on practical coping strategies to manage 
challenging behaviors in MPS. However, some additional 
questions and implications must be addressed in order to 
provide the most effective support for people with MPS 
and their caregivers.
Hoffmann et al. surveyed families of children diagnosed 
with MPS I, II, and III with serious neurological involve-
ment. While the researchers collected some sociodemo-
graphic information about the children with MPS, such 
as their age and gender, they did not fully assess the 
children’s treatment history. Although Hoffmann et  al. 
did report that one child had a history of MPS-specific 
therapy [3], it is unclear whether this therapy included 
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enzyme replacement therapy (ERT), hematopoietic stem 
cell transplantation (HSCT), or another form of medical 
treatment. Furthermore, we are not provided informa-
tion about the medical history of the other 33 children in 
the study. Medical treatment of any kind, including ERT, 
HSCT, anticonvulsants, pain management, treatment for 
spasticity, and surgeries, can significantly alter the behav-
ioral manifestations of MPS [4]. For example, because 
many individuals with neuronopathic MPS have signifi-
cant language impairment, they often exhibit challeng-
ing behaviors to communicate underlying medical issues, 
such as pain [4, 5]. Accordingly, an individual who has 
received more treatment for pain may exhibit fewer chal-
lenging behaviors than someone who has not been ade-
quately treated for pain, which can significantly affect the 
frequency of behavioral symptoms as well as the efficacy 
of the coping strategies reported in this study. It would 
be truly devastating for a family to continually employ 
strategies to distract or calm an aggressive child when the 
behavioral antecedents are actually somatic in nature and 
could be effectively addressed with some form of medical 
intervention. Therefore, future studies must consider the 
medical history of people with MPS to thoroughly exam-
ine the cause of behavior problems and identify effective 
strategies for support.
While Hoffmann et al. provide important information 
about challenging behaviors in children under the age 
of 18, it is unfortunate that they did not include older 
participants in their study. Although the authors do not 
explicitly mention the reasons for this age limit, it is 
important to acknowledge that challenging behaviors 
still occur in people with MPS who are above the age of 
18 [6]. The fact that two adults were excluded from the 
researchers’ analysis [3] indicates that there is both inter-
est and a need to study challenging behaviors in older 
populations. In fact, it can be even more difficult to man-
age behavior problems in adults with MPS because of 
their physical size and strength [4, 7, 8]. Often multiple 
caregivers are needed, including parents, siblings, as well 
as home health aides and direct support professionals [2, 
4]. However, the national shortage of caregivers and dis-
mally low financial compensation for caregiving makes it 
difficult for families to provide care for adults with severe 
behavior problems [9]. With limited resources for sup-
port, many families must consider residential facilities 
when they are no longer able to provide care at home [4, 
6]. Accordingly, future studies must investigate the expe-
riences of families who provide care for adults with MPS 
in order to develop appropriate resources for support.
In addition to researching the experiences of adults 
with MPS, we must also pay attention to other members 
in the family. Hoffmann et al. report that MPS can have a 
slightly negative impact on relationships with healthy sib-
lings [3]. However, of the 20 participants who responded 
to the question about sibling relationships, the majority of 
responses were from parents and only one questionnaire 
was actually completed by a sibling. Siblings may provide 
care for their brothers and sisters with MPS throughout 
life, and the role of primary caregiver often transitions 
to siblings as parents age [7]. Given the limited support 
available for siblings [7, 10], challenging behaviors may 
cause siblings to experience more emotional stress than 
parents and may necessitate unique coping strategies 
specifically for siblings. Accordingly, more research is 
needed to directly investigate the perceptions of siblings 
themselves. Researchers must work closely with patient 
and family organizations to invite siblings to participate 
in future studies.
Some of the coping strategies identified by Hoffmann 
et al. also raise concerns about practicality. Several meas-
ures reported against challenging behaviors require the 
direct involvement of caregivers, such as “calming child 
down,” “giving attention,” “rewarding/punishing/scold-
ing child,” “1:1-supervision,” and “parent sleeping in child 
bed” [3]. While participants perceived many of these 
measures to be effective, these interventions all require 
time and physical presence. Yet Hoffmann et  al. report 
that participants were better able to cope with their 
child’s disorder when they had time alone and outside 
the family [3]. These results seem conflicting: How do 
caregivers get time for themselves when they must con-
stantly provide care and manage the behavior problems 
of MPS? Hoffmann et  al. do not provide information 
about how participants feel actively implementing these 
coping strategies and their overall perceptions of car-
egiver burden. Therefore, qualitative studies are needed 
to examine whether these coping strategies are actu-
ally feasible in practice. Anthropological methods, such 
as participant observation, may be used to report how 
caregivers implement these strategies on a daily basis 
and identify whether these strategies should be recom-
mended for all families.
Interestingly, Hoffmann et al. also report that antipsy-
chotics were prescribed and rated highly effective against 
challenging behaviors [3]. However, previous studies have 
reported that antipsychotics should not be recommended 
for people with MPS because of their limited efficacy and 
potential for adverse side effects [4]. These conflicting 
results make it very difficult for clinicians and families to 
manage the behavior problems of MPS. Further qualita-
tive research may help evaluate how antipsychotics affect 
the lived experiences of people with MPS, which may 
provide further insights on the efficacy of antipsychotics 
for this population.
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While many factors can influence the impact of behav-
ior problems, we must not forget that challenging behav-
iors can cause tremendous social isolation for families. 
My parents and I rarely see extended family, visit with 
friends, or go out in public because of fear that my 
brother will hurt someone. Moreover, support groups 
rarely discuss aggression and other behavior problems, 
making it seem like we are the only family with these dif-
ficult experiences. The research conducted by Hoffmann 
et al. is extremely important because it helps families like 
mine recognize that we are not alone and there are strat-
egies to help cope with challenging behaviors. However, 
the recommendations outlined in this article can help 
studies dig even deeper to understand the broader impact 
of challenging behaviors and identify the most effective 
interventions for support.
Response to: Evaluating strategies 
to manage and endure challenging behaviors 
in mucopolysaccharidoses
Frederik Hoffmann2* Markus Ries3
*Correspondence:  frederik.hoffmann@klinikum-fuerth.de
2 Center for Pediatric and Adolescent Medicine, Klinikum Fürth, 
Jakob-Henle-Straße l, 90766 Fürth, Germany
3 Pediatric Neurology and Metabolic Medicine, Center for Rare Diseases, 
Center for Pediatric and Adolescent Medicine, Heidelberg University Hospital, 
Im Neuenheimer Feld 430, 69120 Heidelberg, Germany 
Dear Professor Palau,
Thank you for letting us have Grant’s response to our 
research. We have studied Grant’s letter with great inter-
est and certainly appreciate his important comments. We 
feel honoured by such scholarly feedback and are happy 
to comment on it.
Grant strongly underlines the urgent need for a bet-
ter understanding of the behavioral problems associ-
ated with neuronopathic Mucopolysaccharidoses (MPS) 
and their deep-reaching effects on affected families, as 
well as the problems in surveying them. He concretely 
illustrates how aggressive behavior further impedes 
the intense and stressful demands on the people caring 
for persons with neuronopathic MPS. His experiences 
conform with the findings of our study, which pinpoint 
out aggressive behavior as one of the most wearing and 
least manageable problems associated with this disorder. 
Furthermore, the social isolation that results from the 
challenging behavior is a core problem with MPS, as it 
reduces external support resources. Accordingly, parents 
have reported an open exposure to the disorder and its 
difficulties as advice to ‘recently diagnosed’ families [3]. 
We agree with Grant, that the awareness of affected fami-
lies’ situation and the removal of taboos seems a cutting-
edge element in the commerce with the disease.
Against the background of patients being intellectually 
disabled and nonverbal, as emphasized in our publica-
tion, behavior such as aggression must be considered as 
communication of indisposition [3, 11]. We have men-
tioned that it is important to address potential physical 
factors first, in order to allow for behavioral strategies to 
work out [3, 4]. In this context, availability by a practi-
tioner, who is familiar with the child and its condition, 
seems crucial. Parents did not report the use of pain 
killers in our study [3]. However, in our clinical experi-
ence we have seen the positive effects of antispastic, 
hence analgetic treatment via baclofen pump on sleep 
difficulties.
We conform with Grant that the individual medical 
history and medical treatment is fundamental for under-
standing child behavior and possible solutions. Yet, a 
wide collection of data will decrease study participants’ 
response rates (a factor that must not be underestimated 
in research intense conditions like MPS). Therefore, the 
study design needed to balance these factors in order 
to answer our research questions. Our primary inter-
est focused on the behavioral phenotype and the collec-
tion of parental experiences. With this aim in mind, all 
medication prompted by parents was presented in the 
publication, each with its estimated effectiveness on dif-
ficult behavior. The high reporting rate of antipsychotic 
medication shows, that its prescription is common in the 
treatment of sleep disturbance and hyperactivity in MPS 
[3]. We have underlined that antipsychotic medication 
may have strong adverse effects, especially in children 
with MPS, and must therefore be prescribed with par-
ticular precaution [3, 4, 12–14]. However, given its high 
estimated effectiveness on challenging behavior, the use 
of antipsychotic medication should not be dismissed 
entirely without careful specialist evaluation. An indi-
vidual (re-)consideration of risks and benefit before and 
after the beginning of such treatment is considered inevi-
table and severe adverse effects may call for a discon-
tinuation of treatment. Medication should be evaluated 
in collaboration with a pediatric psychiatrist. However, 
regional availability of such medical support is often lim-
ited and represents a resource constraint.
Although Enzyme Replacement Therapy (ERT) or 
Hematopoietic Stem Cell Transplantation (HSCT) can 
have an influence on the disease trajectory, its use is 
limited to a minority of affected children [15–18]. In 
our study’s population only one child had received such 
specific therapy [3]. Due to the rarity of the disorder, the 
child’s mother feared to endanger her anonymity. We 
respected her wish for confidentiality and did not state 
the specific therapies her child had received prior to the 
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study. Nevertheless the individual treatment history is 
essential for the understanding of child behavior in MPS.
Symptomatic behavior in MPS shows distinct changes 
over time. Hyperactivity, as one of the core symptoms 
in children, would diminish in the process of ongoing 
neuronal impairment and ultimately lead to a vegeta-
tive state in most patients [19–21]. Our study focused 
on the pediatric behavioral phenotype and referring 
challenges, which lead to the exclusion of adult individ-
uals in our study protocol. We are thankful for Grants 
accentuation, that care demands do not end with the 
age of 18 years but shift towards other challenges. This 
being so, caregiving will tend to be hindered by adult 
patients’ physical strength, whilst overall patient activ-
ity declines. Again, siblings may be called on to take 
responsibility. This underlines the importance of exter-
nal support for affected families in a post-pediatric 
population. We agree with Grant, that studies inves-
tigating challenges of care demands in adult patients 
with MPS are urgently needed.
Our questionnaire addressed caregivers of children 
with MPS. The fact that it was answered mostly by moth-
ers may be representative for mothers being primary car-
egivers in MPS [8]. Grant noted that sibling stress can’t 
be directly measured in our study. In fact, in only one of 
34 cases, a sibling answered our questionnaire herself. As 
illustrated in previous studies, siblings of children with 
chronic conditions rather internalize their stress, trying 
not to further burden their families with their own prob-
lems [11, 22, 23]. Therefore studies directly addressing 
siblings are needed. Furthermore programs to support, 
connect and empower siblings of chronically ill children 
are highly important [24].
Patient care demands high mental and physical efforts 
[8, 11, 25]. Nevertheless, affected families must not 
neglect their own wellbeing and recovery, in order to 
prevent burnout and master ongoing care demands. 
Grant highlights this dilemma by raising concerns about 
the practicability of time-consuming measures. The 
timely and psychological efforts accompanying any cop-
ing measure is highly individual and depends on multi-
ple factors of the patient (degree of disability, extent of 
challenging behavior such as aggression) and caregiver 
(physical and mental robustness, resources) [11]. In our 
study, we have tried to gather parental experiences and 
state possible toeholds in the contact with affected chil-
dren. The evaluation of cost and benefit of specific meas-
ures must be individual and curtailed to distinct needs 
and resources in order to find a balance that allows for 
long-standing care. The conflict of care demands and 
recovery underlines the importance of external support 
for affected families.
The findings of our study may serve as a first step 
towards using parental experience with problems of poor 
manageability. Future studies, ideally in a controlled 
study design, are urgently needed to monitor efficacy, 
safety, practicability and use of specific measures.
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